Demcizumab is a humanized monoclonal antibody designed for the treatment of cancer.
As of 2015, the drug is being developed by OncoMed Pharmaceuticals in non-small-cell lung cancer as well as pancreatic cancer, in collaboration with Celgene.
Mechanism of action
Demcizumab blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy, it is hoped that a more durable anti-tumor response can be achieved than with chemotherapy alone.